NRX Pharmaceuticals, Inc. annual report, FY2023

NRx Pharmaceuticals, Inc. — Form 10-K Summary

Reporting period: Fiscal year ended December 31, 2023. The filing is an annual report, not a standalone fourth-quarter report. NRx is a clinical-stage biopharmaceutical company developing NRX-101, a fixed-dose combination of D-cycloserine and lurasidone, and NRX-100, a proprietary ketamine presentation, primarily for suicidal depression and bipolar depression. The company also is pursuing potential applications in PTSD, chronic pain, and complicated urinary tract infection.

Business Context and Key Developments

NRX-101 retains FDA Fast Track, Breakthrough Therapy, Special Protocol Agreement, and Biomarker Letter of Support designations for suicidal bipolar depression.
NRX-101 is also being explored for complicated UTI and pyelonephritis, supported by in-vitro antimicrobial data and FDA Qualified Infectious Disease Product, Fast Track, and Priority Review designations.
NRx entered into an exclusive worldwide license agreement with Alvogen and Lotus to develop and commercialize NRX-101 for bipolar depression with suicidality. The arrangement provides for up to $330 million of milestone payments and tiered royalties ranging from low- to mid-teens percentages of net sales, subject to conditions.
HOPE Therapeutics was formed to develop and potentially distribute ketamine and related therapies. Management plans to pursue an NDA for ketamine in suicidal depression during the first half of 2024 and has discussed a potential spin-off or separate listing.
The company transferred its solid-dose manufacturing activities from China to Alcami in the United States and established a ketamine manufacturing relationship with Nephron Pharmaceuticals.

Financial Results and Liquidity

Metric	2023	2022	Change
Revenue	$0	$0	No product revenue
Research and development expense	$13.4 million	$17.0 million	Down $3.6 million
General and administrative expense	$14.2 million	$27.3 million	Down $13.1 million
Total operating expenses	$27.8 million	$44.3 million	Down $16.5 million
Net loss	$30.2 million	$39.8 million	Improved by $9.6 million
Net loss per share	$0.40	$0.60	Improved
Net cash used in operating activities	$21.7 million	$39.8 million	Lower cash use
Cash and cash equivalents at year-end	$4.6 million	$20.1 million	Down $15.5 million
Convertible note payable, fair value	$9.2 million	$10.5 million	Down $1.4 million
Stockholders’ equity	$(11.7) million	$7.4 million	Declined $19.1 million

Operating expenses declined primarily because of lower ZYESAMI-related clinical spending, regulatory and process-development fees, legal and professional fees, insurance costs, employee costs, and stock-based compensation. The 2023 net loss included a $2.7 million non-cash loss from the change in fair value of the convertible note. The 2022 comparison benefited from a $4.6 million gain related to expiration of an earnout cash liability.

At December 31, 2023, total assets were $7.3 million, total liabilities were $19.0 million, accumulated deficit was $253.1 million, and working capital deficit was $12.2 million. The company had no revenue-generating approved products and reported substantial doubt about its ability to continue as a going concern for at least twelve months from issuance of the financial statements.

Material Changes Versus 2022

Net loss and operating cash burn improved substantially, but cash declined to $4.6 million and the company moved from positive stockholders’ equity to a $11.7 million deficit.
Research and development spending decreased as the company exited or reduced ZYESAMI-related activities and concentrated on NRX-101 and ketamine development.
General and administrative spending fell by approximately 48%, primarily from lower legal, professional, insurance, stock-based compensation, employee, and consulting costs.
The company raised approximately $9.3 million in 2023 financing proceeds before or net of applicable offering costs, including common stock, warrants, and Series A convertible preferred stock, while repaying approximately $3.1 million of convertible debt.
Common shares outstanding increased from approximately 66.4 million at December 31, 2022 to 83.9 million at December 31, 2023. The filing reported 95,699,780 shares outstanding as of March 25, 2024, before considering subsequent transactions.
NRx settled the GEM arbitration matter by issuing 675,676 common shares, recorded as approximately $0.3 million of settlement expense.
The company continued to face Nasdaq compliance issues, transferred its listing to the Nasdaq Capital Market, and received an extension to demonstrate compliance with the minimum bid price requirement by April 16, 2024.

Debt, Financing, and Subsequent Events

The Streeterville convertible note had an original principal amount of approximately $11.0 million and a reported fair value of $9.2 million at December 31, 2023. The note permits monthly redemptions, potentially in cash or common stock, and carries default and acceleration provisions.
Through March 25, 2024, NRx made approximately $2.9 million of principal and interest payments to Streeterville, including $2.5 million in cash and approximately $0.4 million through issuance of 1,436,472 common shares.
Under the February 2024 amendment, required monthly payments of approximately $0.4 million continued through July 2024, with any remaining balance due in cash by August 31, 2024.
February and March 2024 financings included approximately $1.3 million of net proceeds from a public offering, approximately $0.2 million from the overallotment, approximately $1.0 million from a private placement, and approximately $0.2 million from ATM purchases.
In February 2024, Alvogen agreed to advance $5 million of the initial milestone under the license agreement in exchange for approximately 4.1 million warrants exercisable at $0.40 per share for three years. The filing indicates that an additional $4 million remains tied to the original milestone conditions.
Stockholders approved, and the board authorized, a 1-for-10 reverse stock split on March 21, 2024; the filing states it was not yet effective as of the financial statement disclosure.
Holders converted all 3 million Series A convertible preferred shares into 3 million common shares in March 2024.

Guidance, Outlook, and Unusual Items

Management expected top-line results from the NRX-101 Phase 2b/3 trial in the second quarter of 2024. The trial reached its target enrollment of 74 subjects in the first quarter of 2024.
Management stated that it aimed to submit an NRX-101 NDA on a rolling basis during 2024, but approval is not assured and FDA guidance is not binding.
Management projected positive cash flow by year-end 2024 through partnerships and HOPE Therapeutics activities. The filing provides no firm revenue or earnings guidance and states that substantial additional financing is required.
NRx reported more than 1 million commercial-standard NRX-101 oral doses in inventory and expected five years of room-temperature shelf stability; it also reported a first commercial batch of ketamine in diversion-resistant packaging.
The Alvogen agreement includes termination rights if specified clinical and FDA milestones were not achieved by March 31, 2024. The filing text does not clearly state whether all such conditions were ultimately satisfied.
Prior ZYESAMI development was discontinued and related assets were transferred to Relief Therapeutics. NRx may receive future milestones and royalties, but no royalties had been received through December 31, 2023.

Principal Risks and Contingencies

Going concern and financing: The company has no revenue, recurring losses, negative operating cash flow, a working capital deficit, and substantial doubt regarding continued operations. Future equity financing may materially dilute shareholders.
Clinical and regulatory risk: NRX-101 and NRX-100 remain investigational. Clinical results may fail to replicate prior findings, FDA requirements may change, and approval may be delayed or denied.
Manufacturing risk: NRx relies on third-party manufacturers and has not yet demonstrated sustained large-scale commercial production.
Debt and equity dilution: Streeterville redemption rights can require cash payments or issuance of common shares at a discount to market prices. The company also had approximately 33.2 million common stock warrants outstanding at year-end 2023, in addition to options and preferred-share conversion rights.
Controlled-substance risk: Ketamine is a Schedule III controlled substance subject to DEA quotas, security, recordkeeping, distribution, and manufacturing requirements.
Partner and license risk: Alvogen, Glytech, Sarah Herzog Memorial Hospital, Relief Therapeutics, and other counterparties have contractual rights and termination provisions that could affect development or commercialization.
Legal and listing risk: The company disclosed litigation risks, prior Nasdaq deficiencies, and potential delisting if continued listing conditions are not satisfied.
Accounting and valuation risk: The convertible note and certain warrant liabilities are Level 3 fair-value measurements based on subjective models. The convertible note fair value was identified as a critical audit matter.

Investor Verification Checklist

Verify the status and results of the NRX-101 Phase 2b/3 readout, FDA meetings, NDA submission, and any resulting regulatory action.
Confirm the amount and timing of any Alvogen milestone advance, the remaining $4 million milestone condition, and whether the license remains in effect.
Reconcile current cash, monthly operating burn, Streeterville payments, remaining debt balance, and the cash amount due by August 31, 2024.
Assess the fully diluted share count after the reverse stock split, preferred-share conversion, 2024 offerings, debt conversions, warrants, and options.
Confirm Nasdaq compliance status after the April 16, 2024 deadline and any effect of the reverse stock split.
Evaluate whether HOPE Therapeutics has been legally separated, financed, listed, or otherwise capitalized as described by management.
Review the terms, enforceability, and economic value of the Glytech and Sarah Herzog Memorial Hospital licenses and the Alvogen collaboration.
Distinguish clinical-stage claims and in-vitro results from FDA-approved commercial products; the filing does not report product revenue or any approved NRx product as of December 31, 2023.